Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | How to sequence therapies in CLL after venetoclax discontinuation?

Anthony Mato • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Duvelisib Ibrutinib Idelalisib Venetoclax

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale and results of an international retrospective cohort study of the efficacy of therapies following venetoclax discontinuation in chronic lymphocytic leukemia (CLL). Dr Mato highlights that the therapies they were most interested in included bruton tyrosine kinase inhibitors, phosphoinositide 3-kinase inhibitors and cellular therapy (CAR-T or allo-HSCT). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Anthony Mato

1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals